Related Experiment Video
Updated: Apr 26, 2026

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
Quantitative analysis of pancreatic echogenicity on transabdominal sonography: correlations with metabolic syndrome
Hyeon Tae Jeong1, Mu Sook Lee, Myeong-Jin Kim
1Department of Radiology, Good Morning Internal Clinic, Changwon-si, Republic of Korea.
Purpose:
To attempt a quantitative analysis of pancreatic echogenicity on transabdominal ultrasonography (US) and evaluate the correlation between pancreatic echogenicity and metabolic syndrome (MetS).
Methods:
We retrospectively evaluated transabdominal sonograms from 286 subjects. Mean pancreatic body brightness, mean perihepatic fat brightness, and the pancreato-perihepatic fat index (PPHFI) were measured, and reproducibility was analyzed using intraclass correlation coefficients. Associations between the PPHFI and MetS components were analyzed. The optimal PPHFI cutoff value to predict MetS was calculated.
Results:
Reproducibility was good for mean pancreatic body brightness, mean perihepatic fat brightness, and PPHFI with intraclass correlation coefficients of 0.98, 0.95, and 0.95, respectively. Each MetS component showed a significant association with PPHFI. Waist circumference had the strongest association (r = 0.55, p < 0.0001). PPHFI was significantly higher in the MetS (+) group than the MetS (-) group (p < 0.0001), and PPHFI was an independent factor predicting MetS (p = 0.02; odds ratio, 2.89). The best PPHFI cutoff value to predict MetS was 1.97, with a relatively high negative predictive value of 94.1%.
Conclusions:
We quantitatively analyzed pancreatic echogenicity using the PPHFI on US and found that an increased PPHFI was significantly correlated with MetS. Because increased PPHFI on US may indicate MetS, radiologists and clinicians need to be aware of its implications.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Chronic Pancreatitis II: Collaborative Care
Assessment:

